Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
Sections
Navigation
Media Hero
The pioneering p300/CBP drug development company
Aiming to transform outcomes and quality of life for people with cancer
Landing Hero
Inobrodib
A first-in-class oral anti-cancer drug
Inobrodib is a small molecule inhibitor, taken orally as a simple capsule. It inhibits p300 and CBP through binding into the conserved bromodomain of the twin proteins. This impacts the expression of key cancer drivers including MYC, IRF4 and the androgen receptor (AR) and its variants.
Statistic Set
50+
Epigenetic-related targets
investigated over time by the CellCentric team
1
Drug prioritised, advanced
investigated over time by the CellCentric team
30
Lorem ipsum dolor sit amet
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Text Centred
Lorem ipsum
Inobrodib is a first-in-class clinical inhibitor of p300/CBP and is being applied to treat a number of specific cancer types that are currently under addressed:
WYSIWYG
Stand first — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod temp incididunt ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tortor at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharetra sit amet aliquam.
Paragraph 1 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam. Auctor neque vitae tempus quam pellentesque nec nam aliquam sem. Proin nibh nis condimentum id venenatis a condimentum vitae sapien.
Paragraph 2 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in. Diam vulputate ut pharet sit amet aliquam.
Paragraph 3 — Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidid ut labore et dolore magna aliqua. Odio tempor orci dapibus ultrices in. Morbi leo urna molestie at. Tort at auctor urna nunc id. Sodales neque sodales ut etiam sit amet nisl purus in.
Twitter Feed
Press Release Card Set
Icon Card Set
Haematological cancers
Relapsed/refractory haematological cancers including Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma(NHL) and Myelodysplastic Syndromes (MDS)
Prostate
Cancer
Metastatic Castration Resistant Prostate Cancer (mCRPC). Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
Targeted Tumours
inobrodib can potentially target tumours with amplified expression of certain tumour driving proteins that are regulated by p300/CBP.
Image Split Left
The science behind inobrodib
Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate. The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.
Targeting the bromodomain of p300 and CBP
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.
A differentiated and highly selective inhibitor
Mi ipsum faucibus vitae aliquet nec ullamcorper. Turpis egestas sed tempus urna et pharetra pharetra massa. Metus dictum at tempor commodo. Porttitor leo a diam sollicitudin tempor id eu nisl. Habitant morbi tristique senectus et netus et malesuada fames. Ullamcorper a lacus vestibulum sed arcu.
Image Split Right
Lorem ipsum dolor sit amet, consectetur adipiscing
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ac tortor vitae purus faucibus ornare. Viverra justo nec ultrices dui sapien eget. Metus aliquam eleifend mi in nulla posuere sollicitudin aliquam. Nisi est sit amet facilisis magna etiam tempor.
The science behind inobrodib
Inobrodib was developed by CellCentric from initial hits through to an optimised compound and onto a clinical candidate.
The compound has been evaluated extensively non-clinically, demonstrating its impact on p300/CBP inhibition in vivo.
Latest publications
Scientific publications, Posters and Presentations
View and download posters from recent key conferences
CellCentric’s Director of Cancer Biology talks inobrodib’s mechanism of action in the context of latest efficacy and safety data, treating late/last stage multiple myeloma
Tolerability and clinical activity of novel first in class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/ refractory multiple myeloma
Potent preclinical activity of the EP300/CBP bromodomain
inhibitor CCS1477/inobrodib in multiple myeloma
An open-label phase I/IIa study to evaluate the safety and efficacy of inobrodib
(CCS1477) as monotherapy in patients with relapsed/refractory multiple myeloma
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy and in combination, in patients with advanced haematological malignancies
Views from key opinion leaders and a clinical trial patient on recent positive inobrodib results in relapsed refractory multiple myeloma
Potent pre-clinical and early phase clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma
Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Acute Myeloid Leukemia
p300/CBP bromodomain inhibitor CCS1477 enhances the efficacy of immune checkpoint blockade therapy in cancer treatment
CCS1477, a novel p300/CBP bromodomain inhibitor, enhances efficacy of azacitidine and venetoclax in pre-clinical models of acute myeloid leukaemia and lymphoma
A Phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations
